Title: siRNA Targeting Serine/Threonine Kinase 12
Patent Number: 7,678,896
Filed: June 15, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to STK12."
Title: RNA Interference-Mediated Inhibition of Platelet-Derived Endothelial Growth Factor Gene Expression Using Short Interfering Nucleic Acid
Patent Number: 7,678,897
Filed: Sept. 4, 2008
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
"This invention relates to compounds, compositions, and methods useful for modulating platelet-derived endothelial cell growth factor and/or receptor gene expression using short interfering nucleic acid molecules," the patent's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ECGF1 and/or ECGF1r gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of ECGF1 and/or ECGF1r genes."
Title: Composition for Treatment of Cervix Cancer
Application Number: 20100062051
Filed: Nov. 5, 2007 PCT Filed: Nov. 5, 2007
Lead Inventor: Young Kee Shin, Seoul National University
The invention, the patent application's abstract states, "relates to a composition for the treatment of cervix cancer, more precisely a composition for the treatment of cervix cancer comprising the first active part containing human papillomavirus-specific siRNA as an active ingredient, and the second active part containing an anticancer agent as an active ingredient. The composition for the treatment of cancer of the present invention has better anti-cancer effect than the single therapy of the HPV-specific siRNA or the anticancer agent, and has an advantage of reducing side effects by using the anticancer agent at a low concentration."
Title: Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule
Application Number: 20100062436
Filed: Oct. 31, 2007 PCT Filed: Oct. 31, 2007
Lead Inventor: Florian Jarosch, Noxxon Pharma
The invention relates "to a method for the detection of a nucleic acid molecule comprising at least a strand comprising a sequence of nucleotides in a sample," the patent application's abstract states. Specifically, the method involves "providing a sample containing the nucleic acid molecule; providing a capture probe, whereby the capture probe is at least partially complementary to a part of the nucleic acid molecule; allowing the capture probe to react with the nucleic acid molecule or a part thereof; and detecting whether or not the capture probe is hybridized to the nucleic acid molecule or part thereof."
Title: siRNA Targeting TIE-2
Application Number: 20100062951
Filed: Sept. 17, 2009
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed."
Title: Coated Lipid Complexes and Their Use
Application Number: 20100062967
Filed: Dec. 27, 2005 PCT Filed: Dec. 27, 2005
Lead Inventor: Oliver Keil, Silence Therapeutics
The invention, according to the patent application's abstract, "is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions."
Title: Prompt Nucleic Acid Delivery Carrier Composition
Application Number: 20100063131
Filed: March 26, 2008 PCT Filed: March 26, 2008
Lead Inventor: Hirofumi Takeuchi, Otsuka Pharmaceutical
The invention, the patent application's abstract states, comprises "a carrier composition for nucleic acid delivery [that] can efficiently deliver a nucleic acid [such as an siRNA] into cells when … administered to animal-derived cells or animals."
The carrier "also has low toxicity and high safety, and … is prepared by using a diacylphosphatidylcholine; at least one member selected from the group consisting of cholesterol and derivatives thereof; and an aliphatic primary amine," the abstract notes. "Also, a composition for nucleic acid delivery is prepared by mixing the carrier for nucleic acid delivery with a nucleic acid."
Title: Small Interfering RNA and Pharmaceutical Composition for Treatment of Hepatitis B Comprising the Same
Application Number: 20100063132
Filed: Aug. 20, 2009
Lead Inventor: Meehyein Kim, Mogam Biotechnology Research Institute
The invention "relates to RNA interference-mediated inhibition of hepatitis B virus by short interfering RNA molecules," the patent application's abstract states. "Specially, siRNAs of the … invention … are double-stranded RNAs [and direct] the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules and synthesized siRNA molecules, as well as method of therapeutic treatment for inhibition of HBV gene expression and viral replication by the administration of RNA molecules."
Title: Treatment of Neurodegenerative Disease Through Intracranial Delivery of siRNA
Application Number: 20100063134
Filed: Aug. 27, 2009
Inventor: William Kaemmerer, Medtronic
The invention "provides devices, small interfering RNA, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein," the patent application's abstract states. The invention also provides "valuable small interfering RNA vectors, and methods for treating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, spinocerebellar ataxia Type 1, Type 2, Type 3, and/or dentatorubral-pallidoluysian atrophy."
Title: Lipid Nanoparticle-Based Compositions and Methods for the Delivery of Biologically Active Molecules
Application Number: 20100063308
Filed: Nov. 12, 2009
Lead Inventor: Tongqian Chen, Merck
The invention, the patent application's abstract states, "relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid molecules. The invention also features compositions and methods of use for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of gene expression and/or activity in a subject or organism.
"Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles, and transfection agents that effectively transfect or deliver biologically active molecules, such as … small nucleic acid molecules … to relevant cells and/or tissues, such as in a subject or organism," it adds. "Such novel cationic lipids, microparticles, nanoparticles, and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject, or organism."